Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.

Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG.

Brain Pathol. 2012 Nov;22(6):745-56. doi: 10.1111/j.1750-3639.2012.00585.x. Epub 2012 Apr 12.

2.

Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.

Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG; Arizona Parkinson Disease Consortium..

Exp Neurol. 2013 Feb;240:190-204. doi: 10.1016/j.expneurol.2012.11.020. Epub 2012 Nov 28.

3.

Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders.

Beach TG, White CL 3rd, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH; Arizona Parkinson's Disease Consortium..

Acta Neuropathol. 2009 Feb;117(2):169-74. doi: 10.1007/s00401-008-0450-7. Epub 2008 Nov 4.

4.

A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.

Jellinger KA.

Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Epub 2008 Aug 5. Review.

5.

Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction.

Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG; Arizona Parkinson's Disease Consortium..

Acta Neuropathol. 2009 Jun;117(6):613-34. doi: 10.1007/s00401-009-0538-8. Epub 2009 Apr 28.

6.

Phosphorylated α-synuclein immunoreactivity in the posterior pituitary lobe.

Homma T, Mochizuki Y, Mizutani T.

Neuropathology. 2012 Aug;32(4):385-9. doi: 10.1111/j.1440-1789.2011.01273.x. Epub 2011 Nov 14.

PMID:
22082318
7.

Lewy body-related α-synucleinopathy in the spinal cord of cases with incidental Lewy body disease.

Tamura T, Yoshida M, Hashizume Y, Sobue G.

Neuropathology. 2012 Feb;32(1):13-22. doi: 10.1111/j.1440-1789.2011.01211.x. Epub 2011 Mar 29.

PMID:
22243359
8.

Lewy body-related alpha-synucleinopathy in the aged human brain.

Jellinger KA.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1219-35. Epub 2004 Apr 2.

PMID:
15480835
9.

α-synuclein phosphorylation and truncation are normal events in the adult human brain.

Muntané G, Ferrer I, Martinez-Vicente M.

Neuroscience. 2012 Jan 3;200:106-19. doi: 10.1016/j.neuroscience.2011.10.042. Epub 2011 Oct 29.

PMID:
22079575
10.

alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining.

Gómez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT.

Acta Neuropathol. 2000 Apr;99(4):352-7.

PMID:
10787032
11.

Neuropathologic analysis of Lewy-related α-synucleinopathy in olfactory mucosa.

Funabe S, Takao M, Saito Y, Hatsuta H, Sugiyama M, Ito S, Kanemaru K, Sawabe M, Arai T, Mochizuki H, Hattori N, Murayama S.

Neuropathology. 2013 Feb;33(1):47-58. doi: 10.1111/j.1440-1789.2012.01329.x. Epub 2012 Jun 4.

PMID:
22672612
12.

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.

Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA.

J Neurosci. 2010 Mar 3;30(9):3184-98. doi: 10.1523/JNEUROSCI.5922-09.2010.

13.

Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study.

Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T.

Acta Neuropathol. 2003 Oct;106(4):374-82. Epub 2003 Aug 2.

PMID:
12904992
14.

Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons.

Aldrin-Kirk P, Davidsson M, Holmqvist S, Li JY, Björklund T.

PLoS One. 2014 Jul 7;9(7):e100869. doi: 10.1371/journal.pone.0100869. eCollection 2014.

15.

A critical reappraisal of current staging of Lewy-related pathology in human brain.

Jellinger KA.

Acta Neuropathol. 2008 Jul;116(1):1-16. doi: 10.1007/s00401-008-0406-y. Epub 2008 Jul 1. Review.

PMID:
18592254
16.

Lewy body-related alpha-synucleinopathy in aging.

Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayama S.

J Neuropathol Exp Neurol. 2004 Jul;63(7):742-9.

PMID:
15290899
17.

Formation and development of Lewy pathology: a critical update.

Jellinger KA.

J Neurol. 2009 Aug;256 Suppl 3:270-9. doi: 10.1007/s00415-009-5243-y. Review.

PMID:
19711116
18.

Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.

Jellinger KA.

Acta Neuropathol. 2003 Sep;106(3):191-201. Epub 2003 Jul 5. Erratum in: Acta Neuropathol (Berl). 2003 Dec;106(6):588.

PMID:
12845452
19.

Effect of topographical distribution of α-synuclein pathology on TDP-43 accumulation in Lewy body disease.

Yokota O, Davidson Y, Arai T, Hasegawa M, Akiyama H, Ishizu H, Terada S, Sikkink S, Pickering-Brown S, Mann DM.

Acta Neuropathol. 2010 Dec;120(6):789-801. doi: 10.1007/s00401-010-0731-9. Epub 2010 Jul 29.

PMID:
20669025
20.

Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders.

Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG; Arizona Parkinson's Disease Consortium..

Acta Neuropathol. 2010 Jun;119(6):689-702. doi: 10.1007/s00401-010-0664-3. Epub 2010 Mar 21.

Supplemental Content

Support Center